Report of Foreign Issuer (6-k)
February 20 2018 - 11:45AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 20 February 2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Shares sold to meet tax liabilities
Following the vesting of awards granted in 2015 under the
GlaxoSmithKline 2009 Performance Share Plan on 15 February 2018 and
as notified on 16 February 2018, the notifications that follow
reflect changes in the interests of Persons Discharging Managerial
Responsibilities ('PDMRs') in Ordinary Shares and in American
Depositary Shares ('ADSs') of the Company arising from the sale of
Ordinary Shares or ADSs to meet tax liabilities.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
65,247
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing and Supply
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
33,446
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
16,216
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr B McNamara
|
b)
|
Position/status
|
CEO, Consumer Healthcare
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities further to the vesting of
awards granted in 2015 under the Company's 2009 Performance Share
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$37.4803
|
14,389
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
26,605
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
35,473
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
20,524
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D E Troy
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities further to the vesting of
awards granted in 2015 under the Company's 2009 Performance Share
Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$37.4803
|
31,635
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, R&D
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
73,783
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mrs V A Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities for the vesting
of awards granted in 2015 under the Company's 2009 Performance
Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£13.0726
|
4,544
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
20, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024